Results 1 to 10 of about 13,066 (196)

Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry [PDF]

Haematologica, 2014
Paroxysmal nocturnal hemoglobinuria is a rare, acquired disease associated with hemolytic anemia, bone marrow failure, thrombosis, and, frequently, poor quality of life.
Hubert Schrezenmeier, Petra Muus, Gérard Socié, Jeffrey Szer, Alvaro Urbano-Ispizua, Jaroslaw P. Maciejewski, Robert A. Brodsky, Monica Bessler, Yuzuru Kanakura, Wendell Rosse, Gus Khursigara, Camille Bedrosian, Peter Hillmen   +12 more
doaj   +2 more sources

Paroxysmal Nocturnal Hemoglobinuria

Journal of Nepal Medical Association, 2005
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hemolytic disorder of acquired origin and is clinically manifested by chronic hemolysis, thromboses in various sites, and bone marrow failure.
Buddhi P Paudyal, M Zimmerman, A Karki, H Neupane, G Kayastha   +4 more
doaj   +6 more sources

Paroxysmal nocturnal hemoglobinuria revealed by atypical thromboses: A case of cerebral, hepatic, and portal vein involvement leading to cirrhosis [PDF]

Radiology Case Reports
Paroxysmal nocturnal hemoglobinuria is a rare clonal stem cell disorder characterized by ongoing intravascular hemolysis, frequent bone marrow dysfunction, and a markedly elevated risk of thrombosis.
Majda Malghi, MD, Mehdi Zouaoui, MD, Ibtissam Bamaarouf, MD, Sara Messaoudi, MD, Youssef Hnach, MD, Mbarek Azouaoui, MD, Nourdin Aqodad, MD   +6 more
doaj   +2 more sources

Short-term recurrent coronary artery thrombosis with acute myocardial infarction in a patient with aplastic anemia–paroxysmal nocturnal hemoglobinuria syndrome: a case report [PDF]

Frontiers in Cardiovascular Medicine
BackgroundAcute myocardial infarction commonly occurs in patients with coronary artery disease, but rarely, it can develop under a hypercoagulable state.
Xue-Guo Fu, Yan-Hua Guo, Shi-Chao Wang, Wen-Quan Zhang   +3 more
doaj   +2 more sources

Meningococcal Sepsis in Patient with Paroxysmal Nocturnal Hemoglobinuria during Pegcetacoplan Therapy [PDF]

Emerging Infectious Diseases
Complement C5 inhibitors bring an increased risk for Neisseria infections. A novel complement C3 inhibitor, pegcetacoplan, was recently approved to treat paroxysmal nocturnal hemoglobinuria, a condition commonly treated with complement C5 inhibitors. We
Leo Starck, Vuokko Nummi, Eira Poikonen, Anna-Elina Lehtinen, Pia Kivelä, Nathalie Friberg, Jukka Torvikoski, Maija Toropainen, Seppo Meri   +8 more
doaj   +2 more sources

Herlyn Werner Wunderlich Syndrome Presenting with Ischemic Stroke due to Suspected Paroxysmal Nocturnal Hemoglobinuria: A Case Report

Journal of Nepal Medical Association, 2021
Paroxysmal nocturnal hemoglobinuria can rarely present as cerebral ischemia and stroke due to arterial thrombosis. However, it should be considered in a young patient with bone marrow failure features, systemic thromboses, and hemolysis.
Ayushma Acharya, Prajwala Yogi, Pramod Singh, Tulsi Ram Bhattarai   +3 more
doaj   +1 more source

Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria

Hematology, Transfusion and Cell Therapy, 2021
Paroxysmal nocturnal hemoglobinuria is a chronic, multi-systemic, progressive and life-threatening disease characterized by intravascular hemolysis, thrombotic events, serious infections and bone marrow failure.
Rodolfo D. Cançado, Aderson da Silva Araújo, Alex Freire Sandes, Celso Arrais, Clarisse Lopes de Castro Lobo, Maria Stella Figueiredo, Sandra Fátima Menosi Gualandro, Sara Teresinha Olalla Saad, Fernando Ferreira Costa   +8 more
doaj   +1 more source

Paroxysmal Nocturnal Hemoglobinuria [PDF]

Blood, 2014
AbstractParoxysmal nocturnal hemoglobinuria (PNH) is a rare bone marrow failure disorder that manifests with hemolytic anemia, thrombosis, and peripheral blood cytopenias. The absence of two glycosylphosphatidylinositol (GPI)-anchored proteins, CD55 and CD59, leads to uncontrolled complement activation that accounts for hemolysis and other PNH ...
openaire   +3 more sources

Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes [PDF]

, 2017
C5 blockade by eculizumab prevents complement-mediated intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH). However, C3-bound PNH red blood cells (RBCs), arising in almost all treated patients, may undergo extravascular hemolysis ...
A Hill, A Hill, A Nicholson-Weller, A Roth, AM Risitano, AM Risitano, AM Risitano, AM Risitano, AM Risitano, Antonio M. Risitano, B Nilsson, CE Schoot van der, DJ Araten, DS Holt, E Lach-Trifilieff, E Marchiafava, G Gronowicz, GL Logue, GV Seaman, J Nishimura, J Takeda, JD Tamerius, JE May, JP Atkinson, JV Dacie, L Luzzatto, L Luzzatto, L Luzzatto, M Bessler, M Harboe, M Kono, M Loschi, M Sica, M Sica, MA Lindorfer, Maria De Angioletti, MH Holguin, Michela Sica, MJ Harder, MK Pangburn, MK Pangburn, P Hillmen, P Hillmen, P Hillmen, Patrizia Ricci, PJ Lachmann, PJ Lachmann, RJ Kelly, RL Sparrow, Rosario Notaro, RP Latour de, RP Rother, S Berentsen, SK Krishnan, T Olutogun, T Rondelli, TH Ham, Tommaso Rondelli, UM Reiss, VM Holers, VP Ferreira, WF Rosse, WF Rosse, Z Fishelson, Z Lin   +64 more
core   +2 more sources

Paroxysmal nocturnal hemoglobinuria [PDF]

Vnitřní lékařství, 2018
Paroxysmal nocturnal hemoglobinuria (PNH) results from a deficiency in inhibitors of activated complement. This lack leads to complement mediated intravascular hemolysis, to activation of coagulation system with increased risk of thrombotic complications and to various degree of bone marrow failure.
openaire   +3 more sources